Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:NSCLC molecular testing in Central and Eastern European countries
Avtorji:ID Ryška, Ales (Avtor)
ID Berzinec, Peter (Avtor)
ID Brčić, Luka (Avtor)
ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Avtor)
ID Dziadziuszko, Rafal (Avtor)
ID Gottfried, Maya (Avtor)
ID Kovalszky, Ilona (Avtor)
ID Olszewski, Włodzimierz (Avtor)
ID Oz, Buge (Avtor)
ID Plank, Lukas (Avtor)
ID Tímár, József (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (373,86 KB)
MD5: FDB6E55E6356F21AEEA0C8AC11FAE8C5
 
URL URL - Izvorni URL, za dostop obiščite https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-018-4023-4.pdf
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Background: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC) has highlighted the importance of accurate molecular diagnosis to determine if an actionable genetic alteration is present. Few data are available for Central and Eastern Europe (CEE) on mutation rates, testing rates, and compliance with testing guidelines. Methods: A questionnaire about molecular testing and NSCLC management was distributed to relevant specialists in nine CEE countries, and pathologists were asked to provide the results of EGFR and ALK testing over a 1-year period. Results: A very high proportion of lung cancer cases are confirmed histologically/cytologically (75-100%), and molecular testing of NSCLC samples has been established in all evaluated CEE countries in 2014. Most countries follow national or international guidelines on which patients to test for EGFR mutations and ALK rearrangements. In most centers at that time, testing was undertaken on request of the clinician rather than on the preferred reflex basis. Immunohistochemistry, followed by fluorescent in situ hybridization confirmation of positive cases, has been widely adopted for ALK testing in the region. Limited reimbursement is a significant barrier to molecular testing in the region and a disincentive to reflex testing. Multidisciplinary tumor boards are established in most of the countries and centers, with 75-100% of cases being discussed at a multidisciplinary tumor board at specialized centers. Conclusions: Molecular testing is established throughout the CEE region, but improved and unbiased reimbursement remains a major challenge for the future. Increasing the number of patients reviewed by multidisciplinary boards outside of major centers and access to targeted therapy based on the result of molecular testing are other major challenges.
Ključne besede:non-small-cell lung carcinoma, molecular diagnostic techniques, EGFR mutations, ALK rearrangements, Central Europe, Eastern Europe
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Kraj izida:Velika Britanija
Založnik:Springer Nature
Leto izida:2018
Št. strani:str. 1-8
Številčenje:18
PID:20.500.12556/DiRROS-12788 Novo okno
UDK:616-006
ISSN pri članku:1471-2407
DOI:10.1186/s12885-018-4023-4 Novo okno
COBISS.SI-ID:2048273521 Novo okno
Avtorske pravice:© The Author(s). 2018
Opomba:Soavtorji: Peter Berzinec, Luka Brcic, Tanja Cufer, Rafal Dziadziuszko, Maya Gottfried, Ilona Kovalszky, Włodzimierz Olszewski, Buge Oz, Lukas Plank in Jozsef Timar; Nasl. z nasl. zaslona; Opis vira z dne 12. 4. 2018;
Datum objave v DiRROS:30.11.2020
Število ogledov:2635
Število prenosov:1159
Metapodatki:XML DC-XML DC-RDF
:
RYŠKA, Ales, BERZINEC, Peter, BRČIĆ, Luka, ČUFER, Tanja, DZIADZIUSZKO, Rafal, GOTTFRIED, Maya, KOVALSZKY, Ilona, OLSZEWSKI, Włodzimierz, OZ, Buge, PLANK, Lukas in TÍMÁR, József, 2018, NSCLC molecular testing in Central and Eastern European countries. BMC cancer [na spletu]. 2018. Vol. 18, p. 1–8. [Dostopano 16 marec 2025]. DOI 10.1186/s12885-018-4023-4. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=12788
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:BMC cancer
Skrajšan naslov:BMC Cancer
Založnik:BioMed Central
ISSN:1471-2407
COBISS.SI-ID:2434324 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:09.03.2018

Sekundarni jezik

Jezik:Ni določen
Ključne besede:nedrobnocelični karcinom pljuč, molekularne diagnostične tehnike, mutacije EGFR, Srednja Evropa, Vzhodna Evropa


Nazaj